Rexahn’s portfolio presents unique compounds for a wide variety of conditions from cancer to brain disorders. This highly diversified pipeline promises to bring an improved standard of care in multiple healthcare sectors.
Rexahn’s robust pipeline of clinical-stage and pre-clinical compounds being internally developed or co-developed with a partner:
 |
R&D | Preclinical | Phase I | Phase II | Phase III |  |
|||
 |
|||||||||
 |
Serdaxin® |
Depression |   |
 |
|||||
|
|||||||||
|
Serdaxin® | Parkinson’s Disease | |
|
|||||
|
|||||||||
|
Zoraxel™ | Erectile Dysfunction | |
|
|||||
|
|||||||||
|
Archexin® | Pancreatic Cancer | |
|
|||||
|
|||||||||
|
RX-1792 | Oncology | |
|
|||||
|
|||||||||
|
RX-5902 | Oncology | |
|
|||||
|
|||||||||
|
RX-3117 | Oncology | |
|
|||||
|
|||||||||
|
RX-8243 | Oncology | |
|
|||||
|
|||||||||
|
RX-0201-N | Oncology | |
|
|||||
|
|||||||||
|
RX-0047-N | Oncology | |
|
|||||